US Stock MarketDetailed Quotes

SUPN Supernus Pharmaceuticals

Watchlist

29.870
+0.560+1.91%

Trading Apr 26 13:30 ET

1.63BMarket Cap1493.50P/E (TTM)

Supernus Pharmaceuticals Stock Forum

Moomoo AI

Jan 26 20:21

Supernus Pharmaceuticals' high P/E ratio is sustained by expectations of robust future growth, surpassing market average. Investors' belief in insignificant earnings deterioration risk bolsters the share price.

The Price Is Right For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Moomoo AI

Nov 4, 2023 00:16

Caution is raised with substantial selling of Supernus Pharmaceuticals stock by key insiders and lack of buying in the past year. Insider ownership isn't high, indicating alignment with other shareholders. Evaluate carefully before purchasing due to these factors.

Supernus Pharmaceuticals Repeat Insider Selling Not A Positive Indicator

Bertramie

Oct 12, 2021 15:33

$Supernus Pharmaceuticals(SUPN.US)$
Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall